```html

Kopp’s Disease (Retinitis Pigmentosa)

Overview

Kopp’s disease is a historical eponym for a subset of retinitis pigmentosa (RP) that primarily affects the peripheral retina, leading to progressive loss of night vision and peripheral visual fields. RP is a group of inherited retinal dystrophies characterized by the degeneration of photoreceptor cells (rods first, then cones). The term “Kopp’s disease” is rarely used in modern clinical practice, but many patients still encounter it in older literature.

RP affects roughly 1 in 4,000–5,000 people worldwide (≈0.02% of the population) and is one of the leading causes of inherited blindness in adults.<sup>1</sup> Both males and females are equally affected, and the condition can appear at any age, although symptoms typically begin in childhood or early adulthood.

Symptoms

Symptoms progress slowly over decades, and the exact timeline varies with the genetic subtype. The following list captures the most common clinical features:

Early (rod‑dominant) phase

• Nyctalopia (night blindness): Difficulty seeing in low‑light conditions, often the first sign.
• Peripheral visual field loss: “Tunnel vision” that starts as a narrowing of the side view.
• Photopsia: Occasional flashes of light, especially in dim environments.
• Difficulty with glare: Bright lights may cause discomfort.

Intermediate phase

• Progressive constriction of visual fields: May evolve to “golden ring” visual field defects on testing.
• Reduced contrast sensitivity: Trouble distinguishing subtle shades.
• Difficulty with night driving or reading maps.

Late (cone‑dominant) phase

• Central vision loss: Blurring of central sight, sometimes leading to legal blindness.
• Color vision abnormalities: Desaturation, especially of blues and greens.
• Photophobia: Heightened sensitivity to bright light.
• Reduced visual acuity: May fall below 20/200.

Other possible findings

• Bone‑spicule pigment deposits visible on retinal exam.
• Arteriolar attenuation and optic disc pallor.
• Secondary cataracts (especially posterior subcapsular type).

Causes and Risk Factors

RP, including the form historically called Kopp’s disease, is primarily genetic. Over 80 disease‑causing genes have been identified, many of which are involved in photoreceptor structure, vitamin A metabolism, or ciliary transport.

Inheritance patterns

• Autosomal recessive (≈50%): Both parents carry a single mutated copy; the child inherits two defective genes.
• Autosomal dominant (≈30%): Only one altered gene is needed; often shows variable severity within families.
• X‑linked (≈10%): Mostly affects males; carrier females may have mild signs.
• Sporadic (de novo) mutations: Up to 10% of cases have no family history.

Non‑genetic contributors (rare)

• Retinitis pigmentosa‑like changes secondary to vitamin A deficiency, certain medications (e.g., long‑term chloroquine), or metabolic disorders.
• Traumatic retinal injury that accelerates degeneration.

Risk factors

• Positive family history of RP.
• Consanguineous parentage (higher prevalence of autosomal recessive forms).
• Ethnic groups with founder mutations (e.g., certain Amish or French‑Canadian populations).

Diagnosis

Diagnosis involves a combination of clinical examination, functional testing, and genetic analysis.

1. Clinical eye examination

• Funduscopy: Classic bone‑spicule pigment clumping, attenuated retinal vessels, and optic disc pallor.
• Visual acuity and refraction: Baseline measurement for monitoring progression.

2. Functional tests

• Electroretinogram (ERG): Measures rod and cone responses; reduced rod response is a hallmark.
• Visual field testing (perimetry): Detects progressive peripheral loss.
• Dark adaptation testing: Prolonged time to adapt confirms rod dysfunction.
• Optical coherence tomography (OCT): Shows thinning of outer retinal layers and loss of the photoreceptor ellipsoid zone.
• Fundus autofluorescence (FAF): Highlights areas of retinal pigment epithelium (RPE) stress.

3. Genetic testing

Next‑generation sequencing panels or whole‑exome sequencing can pinpoint the causative mutation in >70% of cases. Genetic confirmation is essential for:

• Prognostic counseling.
• Eligibility for gene‑specific clinical trials (e.g., voretigene‑neparvovec for RPE65‑related RP).
• Family planning and carrier testing.

4. Systemic evaluation (when indicated)

• Audiology testing – some RP forms coexist with hearing loss (Usher syndrome).
• Kidney function – for syndromic RP such as Senior‑Løken or Bardet‑Biedl.

Treatment Options

Currently, no cure exists for RP, but several interventions can slow progression, improve visual function, or manage complications.

1. Pharmacologic therapies

• Vitamin A palmitate (15,000 IU/day): Long‑term studies suggest a modest slowing of ERG decline in non‑RPE65 forms, but it is contraindicated in patients with liver disease or pregnancy.<sup>2</sup>
• Omega‑3 fatty acids (docosahexaenoic acid – DHA): Some evidence of protective effect, though data are not definitive.
• Neuroprotective agents (e.g., ciliary neurotrophic factor – CNTF eye‑drops): Ongoing clinical trials.
• Gene‑replacement therapy: FDA‑approved voretigene neparvovec (Luxturna) for RPE65‑associated RP; sub‑retinal injection restores functional protein in suitable candidates.
• Pharmacologic chaperones (e.g., PTC‑814): Investigational agents targeting specific misfolded proteins.

2. Surgical/Procedural interventions

• Cataract surgery: Posterior subcapsular cataracts are common; removal markedly improves visual acuity.
• Implantable retinal prostheses (e.g., Argus II): For end‑stage RP with bare‑light perception; provides limited but functional vision.
• Low‑vision rehabilitation devices: Magnifiers, telescopic lenses, and electronic visual aids.

3. Lifestyle and supportive measures

• Adopt a diet rich in leafy greens, fish, and antioxidant‑rich fruits.
• Avoid smoking and excessive alcohol, which can exacerbate oxidative stress.
• UV‑protective sunglasses to reduce retinal photo‑oxidation.
• Regular ophthalmology follow‑up (every 6‑12 months) to detect complications early.

Living with Kopp’s Disease (Retinitis Pigmentosa)

Adapting daily life can preserve independence and quality of life.

Vision‑enhancing strategies

• High‑contrast, large‑print materials: Use bold fonts and black‑on‑white or white‑on‑black settings on digital devices.
• Proper lighting: Bright, evenly distributed illumination; task lamps with adjustable intensity.
• Assistive technology: Screen‑reading software (JAWS, VoiceOver), audio books, and smartphone magnification apps.
• Mobility training: Orientation and mobility (O&M) specialists can teach cane techniques and spatial awareness.

Home safety

• Remove tripping hazards; keep pathways clear.
• Label commonly used items with tactile or Braille markers.
• Install motion‑sensor night lights to aid nocturnal navigation.

Emotional and psychosocial support

• Join RP support groups (e.g., Foundation Fighting Blindness, RP Society).
• Consider counseling or therapy to address anxiety or depression, which affect up to 30% of patients with progressive visual loss.<sup>3</sup>
• Educate family members on how to assist without fostering dependency.

Professional considerations

• Discuss workplace accommodations early (e.g., larger monitors, screen‑reading software, flexible lighting).
• Explore vocational rehabilitation programs that assist in job training for low‑vision individuals.

Prevention

Because RP is genetically determined, primary prevention is limited. However, secondary measures can reduce the impact and potential acceleration of disease:

• Genetic counseling: Recommended for affected individuals planning families; carrier testing can inform reproductive choices.
• Avoid vitamin A excess: Hypervitaminosis A can be toxic to the retina; stick to prescribed doses.
• Protect eyes from excessive light: Wear UV‑blocking sunglasses, especially in bright outdoor settings.
• Healthy lifestyle: Balanced diet, regular exercise, and avoidance of smoking help maintain overall retinal health.

Complications

If left unmonitored, RP can lead to several vision‑related and systemic complications:

• Legal blindness: Defined as visual acuity ≤20/200 or visual field ≤20°.
• Cataract formation: Posterior subcapsular cataracts develop in up to 80% of patients by age 40.
• Macular edema: Cystoid macular edema occurs in ~10–15%; may respond to carbonic anhydrase inhibitors or steroids.
• Secondary glaucoma: Rare but possible due to pigment dispersion.
• Psychosocial issues: Depression, social isolation, and reduced employment opportunities.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Retinitis pigmentosa.” Updated 2023. https://www.mayoclinic.org.
2. American Academy of Ophthalmology. “Vitamin A and Retinitis Pigmentosa.” 2022. https://www.aao.org.
3. National Institutes of Health, National Eye Institute. “Vision Loss and Mental Health.” 2021. https://www.nei.nih.gov.
4. U.S. Food & Drug Administration. “Luxturna (voretigene neparvovec) prescribing information.” 2024.
5. World Health Organization. “Blindness and Vision Impairment.” Global data 2022. https://www.who.int.

```